Diagnosis and treatment of acromegaly complications

被引:90
作者
Giustina, A
Casanueva, FF
Cavagnini, F
Chanson, P
Clemmons, D
Frohman, LA
Gaillard, R
Ho, K
Jaquet, P
Kleinberg, DL
Lamberts, SWJ
Lombardi, G
Sheppard, M
Strasburger, CJ
Vance, ML
Wass, JAH
Melmed, S
机构
[1] Univ Brescia, Brescia, Italy
[2] Univ Milan, Milan, Italy
[3] Sch Med, Naples, Italy
[4] Univ Santiago de Compostela, Santiago De Compostela, Spain
[5] Hop Bicetre, Marseille, France
[6] Univ Mediterranee, Marseille, France
[7] Univ N Carolina, Chapel Hill, NC USA
[8] Univ Illinois, Chicago, IL USA
[9] NYU, Med Ctr, New York, NY 10016 USA
[10] Univ Virginia, Charlottesville, VA USA
[11] Univ Calif Los Angeles, Cedars Sinai Res Inst, Sch Med, Los Angeles, CA USA
[12] Univ Hosp, CHUV, Lausanne, Switzerland
[13] Univ Hosp, Rotterdam, Netherlands
[14] Univ Birmingham, Birmingham, W Midlands, England
[15] Radcliffe Infirm, Oxford OX2 6HE, England
关键词
acromegaly; cardiovascular complications; respiratory complications; diabetes; osteoporosis; tumors; somatostatin analogs;
D O I
10.1007/BF03349164
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The Pituitary Society in conjunction with the European Neuroendocrine Association held a consensus workshop to develop guidelines for diagnosis and treatment of the co-morbid complications of acromegaly. Fifty nine pituitary specialists (endocrinologists, neurosurgeons and cardiologists) assessed the current published literature on acromegaly complications in light of recent advances in maintaining tight therapeutic control of GH hypersecretion. The impact of elevated GH levels on cardiovascular disease, hypertension, diabetes, sleep apnea, colon polyps, bone disease, reproductive disorders, and neuropsychologic complications were considered. Guidelines are proposed for effective management of these complications in the context of overall acromegaly control. When appropriate, requirements for prospective evidence-based studies and surveillance database development are enunciated. Effective management of co-morbid acromegaly complications will lead to improved morbidity and mortality in acromegaly. (C) 2003, Editrice Kurtis.
引用
收藏
页码:1242 / 1247
页数:6
相关论文
共 40 条
  • [1] Long-term effects of lanreotide SR and octreotide LAR® on tumour shrinkage and GH hypersecretion in patients with previously untreated acromegaly
    Amato, G
    Mazziotti, G
    Rotondi, M
    Iorio, S
    Doga, M
    Sorvillo, F
    Manganella, G
    Di Salle, F
    Giustina, A
    Carella, C
    [J]. CLINICAL ENDOCRINOLOGY, 2002, 56 (01) : 65 - 71
  • [2] The role of pharmacotherapy in perioperative management of patients with acromegaly
    Ben-Shlomo, A
    Melmed, S
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (03) : 963 - 968
  • [3] Prevalence of diabetes in acromegaly and Cushing's disease
    Biering, H
    Knappe, G
    Gerl, H
    Lochs, H
    [J]. ACTA MEDICA AUSTRIACA, 2000, 27 (01) : 27 - 31
  • [4] SOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profile
    Bruns, C
    Lewis, I
    Briner, U
    Meno-Tetang, G
    Weckbecker, G
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2002, 146 (05) : 707 - 716
  • [5] Surgical complications associated with the endoscopic endonasal transsphenoidal approach for pituitary adenomas
    Cappabianca, P
    Cavallo, LM
    Colao, A
    De Divitiis, E
    [J]. JOURNAL OF NEUROSURGERY, 2002, 97 (02) : 293 - 298
  • [6] Decreased regional blood flow in patients with acromegaly
    Chanson, P
    Megnien, JL
    del Pino, M
    Coirault, C
    Merli, I
    Houdouin, L
    Harris, AG
    Levenson, J
    Lecarpentier, Y
    Simon, A
    Chemla, D
    [J]. CLINICAL ENDOCRINOLOGY, 1998, 49 (06) : 725 - 731
  • [7] Effects of 1-year treatment with octreotide on cardiac performance in patients with acromegaly
    Colao, A
    Cuocolo, A
    Marzullo, P
    Nicolai, E
    Ferone, D
    Florimonte, L
    Salvatore, M
    Lombardi, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1999, 84 (01) : 17 - 23
  • [8] Effect of octreotide pretreatment on surgical outcome in acromegaly
    Colao, A
    Ferone, D
    Cappabianca, P
    DeCaro, MLD
    Marzullo, P
    Monticelli, A
    Alfieri, A
    Merola, B
    Cali, A
    deDivitiis, E
    Lombardi, G
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 1997, 82 (10) : 3308 - 3314
  • [9] Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion
    Del Rio, G
    Velardo, A
    Mascadri, C
    Zalteri, G
    Papi, G
    Menozzi, R
    Giustina, A
    [J]. EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2000, 142 (02) : 179 - 186
  • [10] SPINAL AND PERIPHERAL BONE-MINERAL DENSITIES IN ACROMEGALY - THE EFFECTS OF EXCESS GROWTH-HORMONE AND HYPOGONADISM
    DIAMOND, T
    NERY, L
    POSEN, S
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 111 (07) : 567 - 573